- Time:
Plasma proteomics is a powerful approach for discovering novel protein biomarkers of drug toxicity in various disease contexts. One such biomarker in cardiovascular disease is apolipoprotein M (ApoM), which plays a crucial role in lipid metabolism and transport and is known to have both anti-inflammatory and cardioprotective effects in the body. Studying ApoM using proteomics requires various approaches to understand its expression, modifications, interactions, and functions in the proteome.
In this GEN webinar, Ali Javaheri, MD, will discuss findings from proteomics-based studies that identified ApoM as a mediator of risk in diabetes, heart failure, and chemotherapeutic cardiotoxicity. He’ll discuss the association between ApoM and heart failure outcomes, which has been validated in multiple cohorts using both the SomaScan® Assay and ELISA. During the webinar, you’ll learn about the effects of the chemotherapeutic drug doxorubicin on ApoM levels, and how ApoM heterozygosity affects the regulation of transcription factor EB, which is involved in autophagy and lysosomal biogenesis in the myocardium.
A live Q&A session followed the presentation, offering a chance to pose questions to our expert panelist.
Asst. Professor, Medicine, Cardiovascular Division
Washington Univ. School of Medicine in St. Louis
Webinar produced with support from:
